Article
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
JAMA oncology - 1 Mar 2021
Akamatsu Hiroaki, Toi Yukihiro, Hayashi Hidetoshi, Fujimoto Daichi, Tachihara Motoko, Furuya Naoki, Otani Sakiko, Shimizu Junichi, Katakami Nobuyuki, Azuma Koichi, Miura Naoko, Nishino Kazumi, Hara Satoshi, Teraoka Shunsuke, Morita Satoshi, Nakagawa Kazuhiko, Yamamoto Nobuyuki
Abstract excerpt
IMPORTANCE: Although treatment with first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) plus antiangiogenic inhibitor has shown promising efficacies in patients with EGFR-mutated lung adenocarcinoma, recent single-arm studies have suggested that osimertinib plus antiangiogenic inhibitor might not work synergistically. OBJECTIVE: To explore the efficacy and safety of...
Topics
Join the communities discussing this publication.